仙龙颗粒联合盐酸安罗替尼治疗晚期非小细胞肺癌疗效观察

Observation of Curative Efficacy of Xianlong Granule(仙龙颗粒)Combined with Anlotinib Hydrochloride in Treatment of Advanced Non-Small Cell Lung Cancer

目的:观察仙龙颗粒联合盐酸安罗替尼在晚期非小细胞肺癌(NSCLC)患者三线治疗中的临床疗效。方法:选取晚期NSCLC患者72例,采用随机数字表法分为联合治疗组和对照组各36例。对照组口服盐酸安罗替尼,联合治疗组在对照组的基础上加服仙龙颗粒,两组患者均连续用药2周,停药1周,3周为1个疗程,连续治疗2个疗程。评价两组患者的临床疗效、中医证候疗效,比较两组患者治疗前后KPS评分、免疫功能指标水平,并随访12个月评估患者的无进展生存期(PFS)。结果:联合治疗组和对照组患者的临床有效率、临床控制率、中医证候总改善率分别为25.00%、80.56%、83.33%和13.89%、58.33%、61.11%,其中,联合治疗组临床控制率和中医证候总改善率均高于对照组(P<0.05)。治疗后,联合治疗组和对照组患者KPS评分均高于治疗前(P<0.05),且联合治疗组患者的KPS评分高于对照组(P<0.05);联合治疗组患者免疫球蛋白G(IgG)、免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、CD3^(+)和CD4^(+)水平均高于治疗前(P<0.05),且联合治疗组患者IgG、IgM和CD4^(+)水平均高于对照组(P<0.05)。联合治疗组和对照组患者的中位PFS分别为8.00个月和5.20个月,两组中位PFS比较,差异有统计学意义(P<0.05)。结论:仙龙颗粒联合盐酸安罗替尼在晚期NSCLC三线治疗中的疗效优于单纯应用盐酸安罗替尼,该联合疗法可提高患者的体能状态和免疫功能,改善患者预后。

Objective:To observe the clinical curative efficacy of Xianlong Granule(仙龙颗粒)combined with anlotinib hydrochloride in the third-line treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods:A total of 72 patients with advanced NSCLC were divided into combined treatment group and control group according to the random number table method,with 36 cases in each group.The control group was given oral administration of anlotinib hydrochloride,and the combined treatment group was given Xianlong Granule on the basis of the control group.Patients in both the two groups were treated continuously for 2 weeks and stopped for 1 week,3 weeks as a course of treatment for 2 consecutive courses.After treatment,the clinical curative efficacy and traditional Chinese medicine(TCM)syndrome curative efficacy of the two groups were evaluated,and the changes of KPS scores and immune function measures of the two groups before and after treatment were compared.After 12 months of follow-up,the progression-free survival(PFS)of each group was evaluated.Results:The clinical effective rate,clinical control rate,and total improvement rate of TCM syndrome of the patients in the combined treatment group and the control group were 25.00%,80.56%,83.33%and 13.89%,58.33%,61.11%respectively.The clinical control rate and the total improvement rate of TCM syndrome in the combined treatment group were higher than those in the control group(P<0.05).After treatment,the KPS scores of the patients in the two groups were higher than those before treatment(P<0.05),and the KPS scores of the patients in the combined treatment group were higher than those of the patients in the control group(P<0.05).The levels of IgG,IgA,IgM,CD3^(+)and CD4^(+)of the patients in the combined treatment group were higher than those before treatment(P<0.05),and the levels of IgG,IgM and CD4^(+)of the patients in the combined treatment group were higher than those of the patients in the control group(P<0.05).The median PFS of the patients in the combined treatment group and the control group was 8.00 months and 5.20 months respectively,and the difference of the median PFS between the two groups was statistically significant(P<0.05).Conclusions:The curative efficacy of Xianlong Granule combined with arotinib hydrochloride in the third-line treatment of advanced NSCLC is better than that of arotinib hydrochloride alone.This combined therapy can improve the physical state and immune function of the patients and improve their prognosis.